Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

Synlogic Joins Russell 3000® Index

Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®

Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update

Synlogic Announces Leadership Change

Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria

Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria

Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting

Synlogic Announces Registered Direct Offering of Common Stock

Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis